nach oben

Medical Oncology

Erschienen in:

01.03.2020 | Review Article

Primary pulmonary lymphoepithelioma-like carcinoma

verfasst von: Ying Fan, Chenghui Li, Jing Qin, Hongyang Lu

Erschienen in: Medical Oncology | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Primary pulmonary lymphoepithelioma-like carcinoma (PPLELC) is an extremely rare subtype of non-small-cell lung cancer (NSCLC) but differs from other NSCLC types. Most patients with PPLELC have almost no obvious clinical manifestations, and are often diagnosed in the advanced stage. Complete resection is the standard treatment for cases with early stage disease, while chemotherapy and radiotherapy are effective to some extent in late stage disease. High expression of PD-L1 in PPLELC tumor cells confers immunotherapy an important role in the treatment of PPLELC, and programmed death-1 (PD-1) inhibitors such as nivolumab and pembrolizumab may be optimal options for PPLELC patients. This review focuses on the clinical and pathologic features, treatment, and prognosis of PPLELC.

Y Liang L Wang Y Zhu 2012 Primary pulmonary lymphoepithelioma-like carcinoma: fifty-two patients with long-term follow-up Cancer 118 19 4748 4758PubMed

Lin Z, Situ D, Chang X, et al. Lactate in human sweat: a critical review of research to the present day. J Physiol Sci. 2012;62(1):41–6. https://doi.org/10.1007/s12576-012-0213-z.PubMedPubMedCentral

Hayashi T, Haba R, Tanizawa J, et al. Cytopathologic features and differential diagnostic considerations of primary lymphoepithelioma-like carcinoma of the lung. Diagn Cytopathol. 2012;40(9):820–5.PubMed

Bégin LR, Eskandari J, Joncas J, et al. Epstein-Barr virus related lymphoepithelioma-like carcinoma of lung. J Surg Oncol. 1987;36(4):280–3.PubMed

Han AJ, Xiong M, Zong YS, et al. Association of Epstein-Barr virus with lymphoepithelioma-like carcinoma of the lung in southern China. Am J Clin Pathol. 2000;114(2):220–6.PubMed

Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization Classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10(9):1243–60.PubMed

Jiang WY, Wang R, Pan XF, et al. Clinicopathological features and prognosis of primary pulmonary lymphoepithelioma-like carcinoma. J Thorac Dis. 2016;8(9):2610–6.PubMedPubMedCentral

Sun YH, Lin SW, Hsieh CC, et al. Treatment outcomes of patients with different subtypes of large cell carcinoma of the lung. Ann Thorac Surg. 2014;98(3):1013–9.PubMed

Huang CJ, Chan KY, Lee MY, et al. Computed tomography characteristics of primary pulmonary lymphoepithelioma-like carcinoma. Br J Radiol. 2007;80(958):803–6.PubMed

10.

Curcio LD, Cohen JS, Grannis FW Jr, et al. Primary lymphoepithelioma-like carcinoma of the lung in a child. Report of an Epstein-Barr virus-related neoplasm. Chest. 1997;111(1):250–1.PubMed

11.

Huang CJ, Feng AC, Fang YF, et al. Multimodality treatment and long-term follow-up of the primary pulmonary lymphoepithelioma-like carcinoma. Clin Lung Cancer. 2012;13(5):359–62.PubMed

12.

Chang YL, Wu CT, Shih JY, et al. New aspects in clinicopathologic and oncogene studies of 23 pulmonary lymphoepithelioma-like carcinomas. Am J Surg Pathol. 2002;26(6):715–23.PubMed

13.

Butler AE, Colby TV, Weiss L, et al. Lymphoepithelioma-like carcinoma of the lung. Am J Surg Pathol. 1989;13(8):632–9.PubMed

14.

Chen FF, Yan JJ, Lai WW, et al. Epstein-Barr virus-associated nonsmall cell lung carcinoma: undifferentiated "lymphoepithelioma-like" carcinoma as a distinct entity with better prognosis. Cancer. 1998;82(12):2334–422.PubMed

15.

Wen LI, De-yong KANG, Ying-hong YANG. Primary pulmonary lymphoepithelioma-like carcinoma: a clinicopathological analysis of twenty cases. Chin J Clin Exp Pathol. 2017;33(8):896–7.

16.

He J, Shen J, Pan H, et al. Pulmonary lymphoepithelioma-like carcinoma: a Surveillance, Epidemiology, and End Results database analysis. J Thorac Dis. 2015;7(12):2330–8.PubMedPubMedCentral

17.

Grimes BS, Albores J, Barjaktarevic I. A 65-year-old man with persistent cough and large nodular opacity. Chest. 2015;147(1):e13–e1717.PubMed

18.

Ho JC, Wong MP, Lam WK. Lymphoepithelioma-like carcinoma of the lung. Respirology. 2006;11(5):539–45.PubMed

19.

Bao J-F, Wei X-H, Jiang X-Q. CT features of primary pulmonary lymphoepithelioma-like carcinoma: report of 14 cases and literature review. Chin J CT MRI. 2016;14(11):60–2.

20.

Castro CY, Ostrowski ML, Barrios R, et al. Relationship between Epstein-Barr virus and lymphoepithelioma-like carcinoma of the lung: a clinicopathologic study of 6 cases and review of the literature. Hum Pathol. 2001;32(8):863–72.PubMed

21.

Hong S, Liu D, Luo S, et al. The genomic landscape of Epstein-Barr virus-associated pulmonary lymphoepithelioma-like carcinoma. Nat Commun. 2019;10(1):3108.PubMedPubMedCentral

22.

Liang Y, Shen C, Che G, et al. Primary pulmonary lymphoepithelioma-like carcinoma initially diagnosed as squamous metaplasia: a case report and literature review. Oncol Lett. 2015;9(4):1767–71.PubMedPubMedCentral

23.

Chen B, Chen X, Zhou P, et al. Primary pulmonary lymphoepithelioma-like carcinoma: a rare type of lung cancer with a favorable outcome in comparison to squamous carcinoma. Respir Res. 2019;20(1):262.PubMedPubMedCentral

24.

Ma HL, Wu YP, Lin YB, et al. Computed tomography characteristics of primary pulmonary lymphoepithelioma-like carcinoma in 41 patients. Eur J Radiol. 2013;82(8):1343–6.PubMed

25.

Maruyama H, Tokitsu K, Orino T, et al. Histological variant of lung cancer: two cases of a 7 mm lymphoepithelioma-like carcinoma and a small adenocarcinoma with lymphangiosis carcinomatosa. Histopathology. 2010;57(Suppl 1):231.

26.

Anand A, Zayac A, Curtiss C, et al. Pulmonary lymphoepithelioma-like carcinoma disguised as squamous cell carcinoma. J Thorac Oncol. 2018;13(5):e75–e7676.PubMed

27.

Qin Y, Gao G, Xie X, et al. Clinical features and prognosis of pulmonary lymphoepithelioma-like carcinoma: summary of eighty-five cases. Clin Lung Cancer. 2019;20(3):e329–e337337.PubMed

28.

Da-yun PENG, Qiu-lin LIAO, Xiao-dong CHEN, et al. Clinicopathologic study of lung primary lymphoepithelial-like carcinoma: an analysis of 18 cases. Chin J Clin Res. 2017;30(4):467–70.

29.

Yeh YC, Kao HL, Lee KL, et al. Epstein-Barr Virus-associated pulmonary carcinoma proposing an alternative term and expanding the histologic spectrum of lymphoepithelioma-like carcinoma of the lung. Am J Surg Pathol. 2019;43(2):211–9.PubMed

30.

Chang YL, Yang CY, Lin MW, et al. PD-L1 is highly expressed in lung lymphoepithelioma-like carcinoma: a potential rationale for immunotherapy. Lung Cancer. 2015;88(3):254–9.PubMed

31.

Chang YL, Wu CT, Shih JY, et al. Unique p53 and epidermal growth factor receptor gene mutation status in 46 pulmonary lymphoepithelioma-like carcinomas. Cancer Sci. 2011;102(1):282–7.PubMed

32.

Tong JH, Yeung SF, Chan AW, et al. MET amplification and exon 14 splice site mutation define unique molecular subgroups of non-small cell lung carcinoma with poor prognosis. Clin Cancer Res. 2016;22(12):3048–56.PubMed

33.

Ose N, Kawai T, Ishida D, et al. Pulmonary lymphoepithelioma-like carcinoma with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) fusion gene. Respirol Case Rep. 2016;4(6):e00200.PubMedPubMedCentral

34.

Fang W, Hong S, Chen N, et al. PD-L1 is remarkably over-expressed in EBV-associated pulmonary lymphoepithelioma-like carcinoma and related to poor disease-free survival. Oncotarget. 2015;6(32):33019–32.PubMedPubMedCentral

35.

Xie M, Wu X, Wang F, et al. Clinical significance of plasma epstein-barr virus DNA in pulmonary lymphoepithelioma-like carcinoma (LELC) patients. J Thorac Oncol. 2018;13(2):218–27.PubMed

36.

Abe T, Tanabe Y, Watanabe S, et al. A case of recurrent pulmonary lymphoepithelioma-like carcinoma responding to treatment with CBDCA/paclitaxel combined chemotherapy. Gan To Kagaku Ryoho. 2004;31(8):1215–7.PubMed

37.

Ho JC, Lam WK, Ooi GC, et al. Chemoradiotherapy for advanced lymphoepithelioma-like carcinoma of the lung. Respir Med. 2000;94(10):943–7.PubMed

38.

Gao M, Deng B, Jiang H, et al. Maximal oxygen uptake, sweating and tolerance to exercise in the heat. Int J Biometeorol. 1972;16(5):375–600.

39.

Chan AT, Teo PM, Lam KC, et al. Multimodality treatment of primary lymphoepithelioma-like carcinoma of the lung. Cancer. 1998;83(5):925–9.PubMed

40.

Lin CY, Chen YJ, Hsieh MH, et al. Advanced primary pulmonary lymphoepithelioma-like carcinoma: clinical manifestations, treatment, and outcome. J Thorac Dis. 2017;9:123–8.PubMedPubMedCentral

41.

Ho JC, Lam DC, Wong MK, et al. Capecitabine as salvage treatment for lymphoepithelioma-like carcinoma of lung. J Thorac Oncol. 2009;4(9):1174–7.PubMed

42.

Feng WH, Hong G, Delecluse HJ, et al. Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas. J Virol. 2004;78(4):1893–902.PubMedPubMedCentral

43.

Lin Z, Fu S, Zhou Y, et al. First-line platinum-based chemotherapy and survival outcomes in locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma. Lung Cancer. 2019;137:100–7.PubMed

44.

Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–64.PubMedPubMedCentral

45.

Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;73(17):1627–39.

46.

Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–50.PubMed

47.

Narayanan A, Knollmann FD, Walby JAS, et al. EBV-positive primary pulmonary lymphoepithelioma-like carcinoma response to PD-L1 blockade. Clin Lung Cancer. 2019;20(3):e238–e241241.PubMed

48.

Kumar V, Dave V, Harris J, et al. Response of advanced stage recurrent lymphoepithelioma-like carcinoma to nivolumab. Immunotherapy. 2017;9(12):955–61.PubMed

49.

Ribas A, Hamid O, Daud A, et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA. 2016;315(15):1600–9.PubMed

50.

Kim C, Rajan A, DeBrito PA, et al. Metastatic lymphoepithelioma-like carcinoma of the lung treated with nivolumab: a case report and focused review of literature. Transl Lung Cancer Res. 2016;5(6):720–6.PubMedPubMedCentral

51.

Ho JC, Lam WK, Wong MP, et al. Lymphoepithelioma-like carcinoma of the lung: experience with ten cases. Int J Tuberc Lung Dis. 2004;8(7):890–5.PubMed

52.

Lin L, Lin T, Zeng B. Primary lymphoepithelioma-like carcinoma of the lung: an unusual cancer and clinical outcomes of 14 patients. Oncol Lett. 2017;14(3):3110–6.PubMedPubMedCentral

53.

Qiu ZX, Zhou P, Wang K. Primary pulmonary lymphoepithelioma-like carcinoma response favorably to nivolumab: a case report. Onco Targets Ther. 2019;12:8595–600.PubMedPubMedCentral

54.

Wang L, Long W, Li PF, et al. An elevated peripheral blood monocyte-to-lymphocyte ratio predicts poor prognosis in patients with primary pulmonary lymphoepithelioma-like carcinoma. PLoS ONE. 2015;10(5):e0126269.PubMedPubMedCentral

55.

Jiang L, Wang L, Li PF, et al. Positive expression of programmed death ligand-1 correlates with superior outcomes and might be a therapeutic target in primary pulmonary lymphoepithelioma-like carcinoma. Onco Targets Ther. 2015;8:1451–7.PubMedPubMedCentral

56.

Hekelaar N, van Uffelen R, van Vliet AC, et al. Primary lymphoepithelioma-like carcinoma within an intralobular pulmonary sequestration. Eur Respir J. 2000;16(5):1025–7.PubMed

57.

Liu TC, Chen IS, Lin TK, et al. Erythema elevatum diutinum as a paraneoplastic syndrome in a patient with pulmonary lymphoepithelioma-like carcinoma. Lung Cancer. 2009;63(1):151–3.PubMed

58.

Hsieh MS, Wu CT, Chang YL. Unusual presentation of lymphoepithelioma-like carcinoma of lung as a thin-walled cavity. Ann Thorac Surg. 2013;96(5):1857–9.PubMed

Titel: Primary pulmonary lymphoepithelioma-like carcinoma
verfasst von: Ying Fan
Chenghui Li
Jing Qin
Hongyang Lu
Publikationsdatum: 01.03.2020
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 3/2020
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-020-1344-3

Neu im Fachgebiet Onkologie

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Primary pulmonary lymphoepithelioma-like carcinoma

Abstract

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2020

Perspectives in Oncology: a new article type for Medical Oncology

Preclinical and clinical combination therapies in the treatment of anaplastic thyroid cancer

Could the kinetin riboside be used to inhibit human prostate cell epithelial–mesenchymal transition?

Silymarin inhibited DU145 cells by activating SLIT2 protein and suppressing expression of CXCR4

Polypoidal giant cancer cells in metastatic castration-resistant prostate cancer: observations from the Michigan Legacy Tissue Program

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie